TGFB2 (transforming growth factor beta 2) is a multifunctional cytokine that regulates diverse developmental and physiological processes. Primary functions include angiogenesis, heart development, eye development, and epithelial-to-mesenchymal transition (EMT) 12. Mechanistically, TGFB2 is synthesized as an inactive complex with latency-associated peptide (LAP) and remains sequestered in the extracellular matrix through interactions with LTBP1 and LRRC32/GARP. Upon activation and LAP release, mature TGFB2 binds TGF-β receptors (TGFBR1/2) to transduce signaling via Smad pathways. TGFB2 is critical during nephron induction, where it promotes mesenchymal condensation alongside LIF 3, and maintains microglia identity in the central nervous system 4. Disease relevance is substantial. TGFB2 mutations cause Loeys-Dietz syndrome type 4, an autosomal dominant aortic aneurysm disorder with paradoxically increased TGF-β signaling despite loss-of-function mutations 5. In cancer, TGFB2 upregulation promotes aggressive phenotypes: in gastric cancer via HOXA10-mediated EMT 6, in pancreatic cancer through gemcitabine resistance via lipid metabolism reprogramming 7, and in lung cancer through radioresistance via KDM4C-dependent transcription 8. High TGFB2 expression predicts poor survival in younger pancreatic cancer patients 9. In type 2 diabetes atherosclerosis, impaired MMP2-dependent TGFB2 activation compromises fibrous cap formation 10, identifying TGFB2 as a therapeutic target for both developmental disorders and cancer.